Company Analysis
Sign in

Exicure, Inc. (XCUR)

Nasdaq: XCUR · Pharmaceutical Preparations · Chicago, IL · filing with the SEC since 2017
Full chart Alerts Compare
Grade2.6
◀ Past 1.6● Present 2.1▶ Future 3.6
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

13 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Exicure, Inc.’s names, not what it holds today.

Patents granted
13
13 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 3 in 2024 and 1 in 2023
Applications published
32
since 2001, to Dec 31, 2025
Names they are printed under
3
its own name, a subsidiary
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals6
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
EXICURE, INC. its own name
US, as the owner printed on each patent
9 granted
22 published
Exicure Operating Company a subsidiary
US, as the owner printed on each patent
4 granted
6 published
Exicure, Inc. its own name
named as the applicant on its applications, in US
0 granted
4 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 16, 202411,957,788Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applicationsPharmaceuticalsExicure Operating Company
Jan 30, 202411,883,535Liposomal particles, methods of making same and uses thereofPharmaceuticalsEXICURE, INC.
Jan 9, 202411,866,700Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNAPharmaceuticalsExicure Operating Company
Jul 11, 202311,696,954Synthesis of spherical nucleic acids using lipophilic moietiesPharmaceuticalsExicure Operating Company
Sep 21, 202111,123,294Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applicationsPharmaceuticalsExicure Operating Company
Jan 19, 202110,894,963Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic usePharmaceuticalsEXICURE, INC.
Nov 17, 202010,837,018Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic usePharmaceuticalsEXICURE, INC.
Oct 6, 202010,792,251Liposomal particles, methods of making same and uses thereofPharmaceuticalsEXICURE, INC.
Sep 1, 202010,760,080Anti-TNF compoundsPharmaceuticalsEXICURE, INC.
Jul 7, 202010,704,043Nucleic acid nanostructures with core motifsPharmaceuticalsEXICURE, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 21, 20242024/0382424LIPOSOMAL PARTICLES, METHODS OF MAKING SAME AND USES THEREOFPharmaceuticalsExicure, Inc.
Oct 26, 20232023/0340488TREATMENT OF SKIN DISEASES AND DISORDERS USING INHIBITORS OF KALLIKREIN-RELATED PEPTIDASES (KLK)PharmaceuticalsExicure Operating Company
Oct 19, 20232023/0330129TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS, SPHERICAL NUCLEIC ACID (SNA) TLR9 AGONISTS AND CHECKPOINT INHIBITORS FOR ANTITUMOR THERAPYPharmaceuticalsExicure Operating Company
Nov 17, 20222022/0362398ADMINISTRATION OF SPHERICAL NUCLEIC ACIDS FOR OPHTHALMOLOGICAL USESPharmaceuticalsExicure Operating Company
Nov 3, 20222022/0348917LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SPLICE MODULATIONPharmaceuticalsExicure Operating Company
Aug 18, 20222022/0257512MULTIVALENT DELIVERY OF IMMUNE MODULATORS BY LIPOSOMAL SPHERICAL NUCLEIC ACIDS FOR PROPHYLACTIC OR THERAPEUTIC APPLICATIONSPharmaceuticalsExicure Operating Company · patent 11,957,788 granted from it
Mar 24, 20222022/0088059COMBINED SPHERICAL NUCLEIC ACID AND CHECKPOINT INHIBITOR FOR ANTITUMOR THERAPYPharmaceuticalsExicure Operating Company
Mar 3, 20222022/0064649SPHERICAL NUCLEIC ACID TLR9 AGONISTSPharmaceuticalsEXICURE, INC.
Sep 2, 20212021/0269806IL-1 BETA TARGETING SPHERICAL NUCLEIC ACIDSPharmaceuticalsEXICURE, INC.
Apr 8, 20212021/0102211SPHERICAL NUCLEIC ACID-BASED CONSTRUCTS AS IMMUNOSTIMULATORY AGENTS FOR PROPHYLACTIC AND THERAPEUTIC USEPharmaceuticalsEXICURE, INC.
What it applied for, 2024 to 2025: Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton XCUR · research, not advice